Drug Price Trends for NDC 65162-0806

Average Pharmacy Cost for 65162-0806

Drug Name	NDC	Price/Unit ($)	Unit	Date
No data available in table

Best Wholesale Price for NDC 65162-0806

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TEMOZOLOMIDE 250MG CAP	AvKare, LLC	65162-0806-51	5	249.29	49.85800	2023-09-13 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 65162-0806: Temozolomide by Amneal Pharmaceuticals

The pharmaceutical industry is constantly evolving, with market dynamics and pricing strategies playing crucial roles in shaping the future of drug availability and affordability. In this comprehensive analysis, we'll delve into the market outlook and price projections for the drug with National Drug Code (NDC) 65162-0806, which is Temozolomide manufactured by Amneal Pharmaceuticals LLC.

Understanding NDC 65162-0806: Temozolomide

Temozolomide, identified by NDC 65162-0806, is an important drug in the Amneal Pharmaceuticals LLC portfolio[1]. This medication is primarily used in the treatment of certain types of brain tumors, including glioblastoma multiforme in adults and refractory anaplastic astrocytoma.

Key Features of Temozolomide (NDC 65162-0806)

• Manufacturer: Amneal Pharmaceuticals LLC
• Drug Name: Temozolomide
• NDC: 65162-0806
• Current Status: Active (Not Deleted)[1]

Market Trends Affecting Temozolomide Pricing

The pricing of Temozolomide, like many other prescription drugs, is influenced by various market trends and factors. Understanding these trends is crucial for predicting future price movements and market positioning.

Pharmaceutical Industry Trends for 2025

As we look towards 2025, several key trends are expected to shape the pharmaceutical industry:

1. Continued focus on personalized medicine
2. Advancements in AI and data analytics
3. Increased emphasis on value-based pricing
4. Growing importance of biosimilars and generics
5. Shift towards preventive and predictive healthcare

Industry practitioners largely agree on the key trends shaping the future of pharma. As shifts in the broader health ecosystem unfold, five immediate dynamics stand out in determining the pharma business model of the future[3].

These trends are likely to influence the pricing strategies for drugs like Temozolomide, potentially leading to more nuanced and value-based pricing models.

Price Change Patterns in the Pharmaceutical Industry

To better understand potential price projections for Temozolomide, it's important to analyze general price change patterns in the pharmaceutical industry.

Recent Price Change Trends

From January 2022 to January 2023, the average price increase for prescription drugs was 15.2%, translating to an average increase of $590[6]. However, it's crucial to note that price changes can vary significantly between single-source and multi-source drugs.

• Single-source drugs: Average price increase of 7.4% ($958)
• Multi-source drugs: Average price increase of 26.0% ($69)[6]

Given that Temozolomide is still under patent protection, it's more likely to follow the pricing trends of single-source drugs.

Factors Influencing Temozolomide Pricing

Several factors specific to Temozolomide and its market position could influence its future pricing:

1. Patent status and potential generic competition
2. Manufacturing costs and supply chain dynamics
3. Demand fluctuations based on cancer incidence rates
4. Reimbursement policies of major healthcare payers
5. Regulatory changes and drug pricing reforms

Impact of Medicare Drug Price Negotiation Program

The implementation of the Medicare Drug Price Negotiation Program could have significant implications for drug pricing, including Temozolomide. Beginning in January 2026, negotiated prices for the first 10 selected drugs will go into effect in Medicare Part D[2].

While Temozolomide is not currently on the list of drugs selected for the first round of negotiations, the program's expansion in future years could potentially impact its pricing.

Market Analysis for Temozolomide

To project the market outlook for Temozolomide, we need to consider various factors including current market position, competitive landscape, and growth potential.

Current Market Position

Temozolomide, as a crucial treatment for certain brain cancers, holds a significant position in the oncology drug market. Its effectiveness in treating glioblastoma multiforme, one of the most aggressive forms of brain cancer, ensures a steady demand.

Competitive Landscape

While Temozolomide remains a key player in brain cancer treatment, the oncology market is highly competitive and rapidly evolving. Emerging therapies, including immunotherapies and targeted treatments, could potentially impact Temozolomide's market share in the coming years.

Growth Potential

The growth potential for Temozolomide is closely tied to:

1. Advancements in personalized medicine for cancer treatment
2. Expansion of indications for use in other types of cancers
3. Combination therapies incorporating Temozolomide
4. Market expansion in developing countries with growing healthcare infrastructure

Price Projections for NDC 65162-0806

Based on the analysis of industry trends, pricing patterns, and factors specific to Temozolomide, we can make some projections about its future pricing.

Short-term Price Outlook (1-2 years)

In the short term, Temozolomide prices are likely to follow the general trend of single-source drugs, with potential annual increases in the range of 7-8%. This would translate to:

• 2025 projected price increase: Approximately $700-$800 per unit

Medium-term Price Outlook (3-5 years)

The medium-term outlook is more uncertain due to potential regulatory changes and the possible introduction of the Medicare Drug Price Negotiation Program. However, we can estimate:

• 2026-2028 projected annual price increases: 5-6% per year, accounting for potential downward pressure from negotiations and reforms

Long-term Price Outlook (5+ years)

Long-term projections are highly speculative but could be influenced by:

1. Patent expiration and generic entry
2. Emergence of new competing therapies
3. Shifts in cancer treatment paradigms
4. Global market expansion

Strategies for Stakeholders

Given the projected market dynamics and pricing trends for Temozolomide, various stakeholders should consider the following strategies:

For Pharmaceutical Companies

1. Invest in research to expand Temozolomide's indications
2. Develop combination therapies to enhance efficacy
3. Implement value-based pricing models
4. Prepare for potential price negotiations with Medicare

For Healthcare Providers

1. Stay informed about emerging alternatives to Temozolomide
2. Advocate for patient access to affordable treatment options
3. Participate in clinical trials for new brain cancer therapies

For Patients and Patient Advocacy Groups

1. Monitor policy changes that may affect drug pricing
2. Engage with lawmakers to support affordable drug pricing initiatives
3. Explore patient assistance programs for Temozolomide

The Role of AI and Data Analytics in Drug Pricing

As we move towards 2025 and beyond, the role of AI and data analytics in shaping drug pricing strategies is expected to grow significantly. These technologies can help in:

1. Predicting market demand more accurately
2. Optimizing pricing strategies based on real-world evidence
3. Identifying potential new indications for existing drugs like Temozolomide
4. Streamlining the drug development process, potentially reducing costs

From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech industry in 2025[7].

The integration of AI and data analytics could lead to more dynamic and responsive pricing models for drugs like Temozolomide, potentially balancing profitability with improved patient access.

Global Market Considerations for Temozolomide

While our analysis has primarily focused on the U.S. market, it's crucial to consider global market dynamics when projecting the future of Temozolomide pricing.

International Price Comparisons

Studies have consistently shown that U.S. drug prices are considerably higher than those in other countries[8]. As global pressure mounts for more equitable drug pricing, this could impact future pricing strategies for Temozolomide, potentially leading to:

1. More uniform global pricing strategies
2. Increased pressure for U.S. price reductions
3. Expansion into emerging markets with adapted pricing models

Impact of Global Health Crises

The COVID-19 pandemic has highlighted the importance of robust and flexible pharmaceutical supply chains. Future pricing and availability of drugs like Temozolomide could be influenced by:

1. Investments in local manufacturing capabilities
2. Stockpiling of critical medications
3. International cooperation in drug development and distribution

Regulatory Landscape and Its Impact on Temozolomide Pricing

The regulatory environment plays a crucial role in shaping drug pricing strategies. For Temozolomide (NDC 65162-0806), several regulatory factors could influence its future pricing:

FDA Regulations

The FDA's National Drug Code Directory, which includes information about Temozolomide, is a key resource for tracking drug products[9]. Any changes in FDA regulations regarding drug approval, labeling, or post-market surveillance could impact the costs associated with maintaining Temozolomide's market presence.

Drug Pricing Reform Initiatives

Ongoing discussions about drug pricing reform in the United States could significantly affect the pricing strategy for Temozolomide. Potential reforms include:

1. International reference pricing
2. Out-of-pocket cost caps for patients
3. Increased transparency in drug pricing

Medicare Negotiation Impact

The implementation of Medicare drug price negotiations could have far-reaching effects on the pharmaceutical industry. While Temozolomide is not currently selected for negotiation, the program's expansion could impact its pricing in the future[10].

Key Takeaways

1. Temozolomide (NDC 65162-0806) remains an important drug in the treatment of certain brain cancers.
2. Short-term price increases are likely to follow industry trends for single-source drugs, with potential annual increases of 7-8%.
3. Medium to long-term pricing will be influenced by factors such as regulatory changes, potential generic entry, and evolving cancer treatment paradigms.
4. The implementation of the Medicare Drug Price Negotiation Program could significantly impact pharmaceutical pricing strategies.
5. AI and data analytics are expected to play an increasing role in drug pricing and market analysis.
6. Global market considerations and international price comparisons may influence future pricing strategies.
7. Stakeholders should stay informed about market trends and regulatory changes to make informed decisions regarding Temozolomide.

FAQs

1. Q: What is the current status of Temozolomide (NDC 65162-0806) in the market? A: Temozolomide (NDC 65162-0806) is currently an active drug manufactured by Amneal Pharmaceuticals LLC, primarily used for treating certain types of brain tumors.

2. Q: How might the Medicare Drug Price Negotiation Program affect Temozolomide pricing? A: While Temozolomide is not currently selected for negotiation, the program's future expansion could potentially impact its pricing, possibly leading to more competitive pricing in the Medicare market.

3. Q: What role will AI play in future drug pricing strategies? A: AI is expected to significantly influence drug pricing by enabling more accurate demand predictions, optimizing pricing strategies based on real-world evidence, and potentially streamlining drug development processes.

4. Q: How do U.S. drug prices compare to international prices, and how might this affect Temozolomide? A: U.S. drug prices are generally higher than in other countries. This disparity could lead to increased pressure for more uniform global pricing strategies or potential U.S. price reductions for drugs like Temozolomide.

5. Q: What factors should stakeholders consider when planning for the future of Temozolomide? A: Stakeholders should consider factors such as potential regulatory changes, the evolving competitive landscape in cancer treatments, global market dynamics, and the increasing role of data analytics in drug pricing and development.

Sources cited: [1] https://www.findacode.com/ndc/labelers/Amneal_Pharmaceuticals,_LLC--65162 [2] https://aspe.hhs.gov/sites/default/files/documents/3e8abec86039ac0ed674a8c5fac492e3/price-change-over-time-brief.pdf [3] https://www.pwc.com/us/en/industries/pharma-life-sciences/pharmaceutical-industry-trends.html [6] https://aspe.hhs.gov/sites/default/files/documents/0cdd88059165eef3bed1fc587a0fd68a/aspe-drug-price-tracking-brief.pdf [7] https://www.labiotech.eu/in-depth/biotech-trends-2025/ [8] https://aspe.hhs.gov/sites/default/files/documents/bc582e25376d714694524a492fb15f36/international-prescription-drug-price-comparisons.pdf [9] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory [10] https://www.cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf